NASDAQ:ARDX Ardelyx (ARDX) Stock Price, News & Analysis → Elon Musk Secret Crypto Plot Exposed (From Crypto 101 Media) (Ad) Free ARDX Stock Alerts $9.31 +0.16 (+1.75%) (As of 05/7/2024 ET) Add Compare Share Share Today's Range$9.05▼$9.3350-Day Range$6.31▼$9.5952-Week Range$3.16▼$10.13Volume4.87 million shsAverage Volume6.30 million shsMarket Capitalization$2.18 billionP/E RatioN/ADividend YieldN/APrice Target$12.81 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Ardelyx alerts: Email Address Ardelyx MarketRank™ Stock AnalysisAnalyst RatingBuy3.11 Rating ScoreUpside/Downside37.6% Upside$12.81 Price TargetShort InterestBearish14.50% of Shares Sold ShortDividend StrengthN/ASustainability-1.32Upright™ Environmental ScoreNews Sentiment0.68Based on 31 Articles This WeekInsider TradingSelling Shares$1.73 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.44) to $0.13 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.54 out of 5 starsMedical Sector88th out of 903 stocksPharmaceutical Preparations Industry26th out of 420 stocks 4.6 Analyst's Opinion Consensus RatingArdelyx has received a consensus rating of Buy. The company's average rating score is 3.11, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageArdelyx has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Ardelyx's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted14.50% of the outstanding shares of Ardelyx have been sold short.Short Interest Ratio / Days to CoverArdelyx has a short interest ratio ("days to cover") of 6.2.Change versus previous monthShort interest in Ardelyx has recently decreased by 3.11%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldArdelyx does not currently pay a dividend.Dividend GrowthArdelyx does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreArdelyx has received a 66.92% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physical health" and "Constipation medication (A06)" products. See details.Environmental SustainabilityThe Environmental Impact score for Ardelyx is -1.32. Previous Next 2.6 News and Social Media Coverage News SentimentArdelyx has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 31 news articles for Ardelyx this week, compared to 5 articles on an average week.Search InterestOnly 34 people have searched for ARDX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 16 people have added Ardelyx to their MarketBeat watchlist in the last 30 days. This is a decrease of -27% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ardelyx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,734,098.00 in company stock.Percentage Held by InsidersOnly 5.50% of the stock of Ardelyx is held by insiders.Percentage Held by Institutions58.92% of the stock of Ardelyx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Ardelyx's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Ardelyx are expected to grow in the coming year, from ($0.44) to $0.13 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ardelyx is -33.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ardelyx is -33.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArdelyx has a P/B Ratio of 12.93. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Ardelyx's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Crash Insurance” For Your RetirementWhen it comes to retirement, everyone fears one thing… Outliving their retirement savings. You'll discover conservative, beginner-friendly options strategies which could help to cash flow your stock portfolio. Click here to register for free. About Ardelyx Stock (NASDAQ:ARDX)Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.Read More ARDX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ARDX Stock News HeadlinesMay 2, 2024 | insidertrades.comInsider Selling: Ardelyx, Inc. (NASDAQ:ARDX) CEO Sells 30,000 Shares of StockApril 18, 2024 | insidertrades.comArdelyx, Inc. (NASDAQ:ARDX) CEO Michael Raab Sells 7,500 SharesMay 8, 2024 | Banyan Hill Publishing (Ad)The Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.May 7, 2024 | globenewswire.comArdelyx to Present Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with Irritable Bowel Syndrome with Constipation at the 2024 Digestive Disease Week ConferenceMay 6, 2024 | americanbankingnews.comFY2025 Earnings Estimate for Ardelyx, Inc. (NASDAQ:ARDX) Issued By Leerink PartnrsMay 6, 2024 | americanbankingnews.comBrokers Offer Predictions for Ardelyx, Inc.'s Q2 2025 Earnings (NASDAQ:ARDX)May 5, 2024 | americanbankingnews.comArdelyx (NASDAQ:ARDX) PT Raised to $14.00May 5, 2024 | americanbankingnews.comWedbush Increases Ardelyx (NASDAQ:ARDX) Price Target to $15.00May 8, 2024 | Banyan Hill Publishing (Ad)The Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.May 4, 2024 | finance.yahoo.comArdelyx First Quarter 2024 Earnings: Beats ExpectationsMay 4, 2024 | finance.yahoo.comArdelyx, Inc. (NASDAQ:ARDX) Q1 2024 Earnings Call TranscriptMay 4, 2024 | americanbankingnews.comArdelyx (NASDAQ:ARDX) Shares Gap Up After Strong EarningsMay 4, 2024 | americanbankingnews.comInvestors Purchase High Volume of Ardelyx Call Options (NASDAQ:ARDX)May 3, 2024 | seekingalpha.comArdelyx Stock: A Crowded Market Curbs The Enthusiasm (Rating Downgrade)May 3, 2024 | marketwatch.comArdelyx Shares Rally Premarket as 1Q Revenue Tops Street ViewsMay 3, 2024 | americanbankingnews.comMichael Raab Sells 30,000 Shares of Ardelyx, Inc. (NASDAQ:ARDX) StockMay 2, 2024 | investorplace.comARDX Stock Earnings: Ardelyx Beats EPS, Beats Revenue for Q1 2024May 2, 2024 | sfgate.comArdelyx: Q1 Earnings SnapshotMay 2, 2024 | globenewswire.comArdelyx Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 1, 2024 | globenewswire.comArdelyx to Present Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the National Kidney Foundation 2024 Spring Clinical MeetingsMay 1, 2024 | americanbankingnews.comArdelyx, Inc. (NASDAQ:ARDX) Receives Average Recommendation of "Buy" from BrokeragesApril 23, 2024 | finance.yahoo.comArdelyx's (NASDAQ:ARDX) investors will be pleased with their favorable 91% return over the last five yearsApril 18, 2024 | investing.comArdelyx CEO Michael Raab sells $52,923 in company stockApril 18, 2024 | finance.yahoo.comArdelyx to Report First Quarter 2024 Financial Results on May 2, 2024April 16, 2024 | finance.yahoo.comArdelyx, Inc. (ARDX) Interactive Stock Chart - Yahoo FinanceApril 5, 2024 | markets.businessinsider.comA Closer Look at 6 Analyst Recommendations For ArdelyxApril 2, 2024 | investorplace.comThe Millionaire's Shortcut: 3 Stocks to Transform Your Portfolio This MonthSee More Headlines Receive ARDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ardelyx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Today5/07/2024Next Earnings (Estimated)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ARDX CUSIPN/A CIK1437402 Webwww.ardelyx.com Phone(510) 745-1700Fax510-745-0493Employees267Year Founded2007Price Target and Rating Average Stock Price Target$12.81 High Stock Price Target$15.00 Low Stock Price Target$8.50 Potential Upside/Downside+37.6%Consensus RatingBuy Rating Score (0-4)3.11 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($0.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-66,070,000.00 Net Margins-41.36% Pretax Margin-40.95% Return on Equity-41.65% Return on Assets-23.08% Debt Debt-to-Equity Ratio0.66 Current Ratio4.53 Quick Ratio4.36 Sales & Book Value Annual Sales$124.46 million Price / Sales17.50 Cash FlowN/A Price / Cash FlowN/A Book Value$0.72 per share Price / Book12.93Miscellaneous Outstanding Shares233,980,000Free Float221,108,000Market Cap$2.18 billion OptionableOptionable Beta0.87 Social Links The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Michael G. Raab (Age 59)President, CEO & Director Comp: $1.28MMs. Susan Rodriguez (Age 59)Chief Commercial Officer Comp: $760.77kDr. Laura A. Williams M.D. (Age 60)M.P.H., Chief Medical Officer Comp: $873.8kMr. Justin A. Renz CPA (Age 52)MBA, Chief Financial & Operations Officer and Treasurer Comp: $623.7kMr. Robert FelschSenior VP of Finance & Chief Accounting OfficerMs. Elizabeth A. Grammer Esq. (Age 60)Chief Legal & Administrative Officer and Secretary Comp: $623.7kMs. Caitlin LowieVice President of Corporate Communications & Investor RelationsMs. Charon Spencer Sr.Chief Human Resources OfficerMr. David P. Rosenbaum (Age 63)Chief Development Officer Comp: $645.4kMr. Robert C. Blanks (Age 64)Chief Regulatory Affairs & Quality Assurance Officer Comp: $590.8kMore ExecutivesKey CompetitorsKeros TherapeuticsNASDAQ:KROSRocket PharmaceuticalsNASDAQ:RCKTDeciphera PharmaceuticalsNASDAQ:DCPHArvinasNASDAQ:ARVNGeronNASDAQ:GERNView All CompetitorsInsiders & InstitutionsInspire Investing LLCSold 13,417 shares on 5/8/2024Ownership: 0.021%Swiss National BankBought 28,900 shares on 5/7/2024Ownership: 0.196%SG Americas Securities LLCSold 80,294 shares on 5/7/2024Ownership: 0.010%Laura A WilliamsSold 39,949 sharesTotal: $333,574.15 ($8.35/share)BNP Paribas Financial MarketsSold 74,101 shares on 5/1/2024Ownership: 0.245%View All Insider TransactionsView All Institutional Transactions ARDX Stock Analysis - Frequently Asked Questions Should I buy or sell Ardelyx stock right now? 9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ardelyx in the last twelve months. There are currently 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ARDX shares. View ARDX analyst ratings or view top-rated stocks. What is Ardelyx's stock price target for 2024? 9 brokerages have issued 12-month target prices for Ardelyx's shares. Their ARDX share price targets range from $8.50 to $15.00. On average, they anticipate the company's share price to reach $12.81 in the next twelve months. This suggests a possible upside of 37.6% from the stock's current price. View analysts price targets for ARDX or view top-rated stocks among Wall Street analysts. How have ARDX shares performed in 2024? Ardelyx's stock was trading at $6.20 at the beginning of 2024. Since then, ARDX stock has increased by 50.2% and is now trading at $9.31. View the best growth stocks for 2024 here. When is Ardelyx's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024. View our ARDX earnings forecast. How were Ardelyx's earnings last quarter? Ardelyx, Inc. (NASDAQ:ARDX) released its earnings results on Thursday, May, 2nd. The biopharmaceutical company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.02. The biopharmaceutical company earned $46 million during the quarter, compared to analysts' expectations of $36.40 million. Ardelyx had a negative trailing twelve-month return on equity of 41.65% and a negative net margin of 41.36%. The firm's quarterly revenue was up 303.5% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.13) earnings per share. What ETFs hold Ardelyx's stock? ETFs with the largest weight of Ardelyx (NASDAQ:ARDX) stock in their portfolio include Simplify Propel Opportunities ETF (SURI), Virtus LifeSci Biotech Clinical Trials ETF (BBC) and First Trust Small Cap Growth AlphaDEX Fund (FYC).First Trust Small Cap Core AlphaDEX Fund (FYX). What other stocks do shareholders of Ardelyx own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ardelyx investors own include Micron Technology (MU), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Corbus Pharmaceuticals (CRBP), TherapeuticsMD (TXMD) and Advanced Micro Devices (AMD). Who are Ardelyx's major shareholders? Ardelyx's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BNP Paribas Financial Markets (0.25%), Swiss National Bank (0.20%), Hennion & Walsh Asset Management Inc. (0.19%), Simplex Trading LLC (0.00%), PFG Investments LLC (0.06%) and Principal Financial Group Inc. (0.05%). Insiders that own company stock include David P Rosenbaum, Elizabeth A Grammer, Jeffrey W Jacobs, Justin A Renz, Laura A Williams, Michael Raab, Robert Blanks, Robert Ora Felsch, Scott D Sandell and Susan Rodriguez. View institutional ownership trends. How do I buy shares of Ardelyx? Shares of ARDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ARDX) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersShocking: One AI startup's revenue could surge 4,735%Manward PressBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsGold Set to EXPLODE!Gold Safe ExchangeThe #1 lithium battery stock to have on your radar in 2024!Smallcaps DailyAI “wealth window” is closing June 25thParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ardelyx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
